Addictovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
Inserm Unit 1300, HP2, University Grenoble Alpes, Grenoble, France.
Br J Clin Pharmacol. 2022 Nov;88(11):4937-4940. doi: 10.1111/bcp.15430. Epub 2022 Jun 14.
Ketamine and dextromethorphan are widely abused psychoactive substances. Inhibition of N-methyl-d-aspartate receptors (NMDARs) results in neurobehavioural effects including hallucinations, "out of body" sensations and dissociative effects. However, little is known about a possible extended addictive class effect linked to pharmacologically-related amino-adamantane derivatives (e.g., amantadine and memantine). Using a quasi-Bayesian analytic method, we investigated the potential association between the use of approved NMDAR antagonists (i.e., dextromethorphan, ketamine, amantadine and memantine) and the reporting of drug abuse and dependence in the WHO pharmacovigilance database (VigiBase®), which includes >21 million individual case safety reports collected from >130 countries. This disproportionality analysis identified a significant association for all investigated drugs: dextromethorphan (IC = 3.03 [2.97-3.09]), ketamine (IC = 1.70 [1.57-1.83]), amantadine (IC = 0.21 [0.06-0.35]) and memantine (IC = 0.27 [0.13-0.40]), suggesting a class effect for drug abuse and dependence. This first signal requires further investigations, but health professionals need to be alert to the potential of abuse of NMDAR antagonists, especially in the current "opioid epidemic" context, due to their growing interest as non-opioid antinociceptive drugs.
氯胺酮和右美沙芬是广泛滥用的精神活性物质。抑制 N-甲基-D-天冬氨酸受体(NMDAR)会导致神经行为效应,包括幻觉、“出体”感和分离效应。然而,对于与药理学相关的氨基金刚烷衍生物(如金刚烷胺和美金刚)可能存在的扩展成瘾类药物效应,人们知之甚少。本研究采用准贝叶斯分析方法,研究了在世界卫生组织药物警戒数据库(VigiBase®)中,使用批准的 NMDAR 拮抗剂(即右美沙芬、氯胺酮、金刚烷胺和美金刚)与药物滥用和药物依赖报告之间的潜在关联,该数据库包含来自 130 多个国家/地区的超过 2100 万份个体病例安全性报告。这项比例失衡分析确定了所有研究药物的显著关联:右美沙芬(IC = 3.03 [2.97-3.09])、氯胺酮(IC = 1.70 [1.57-1.83])、金刚烷胺(IC = 0.21 [0.06-0.35])和美金刚(IC = 0.27 [0.13-0.40]),提示存在药物滥用和药物依赖的类效应。这是第一个信号,需要进一步调查,但鉴于非阿片类镇痛药的需求不断增加,健康专业人员需要警惕 NMDAR 拮抗剂滥用的潜在风险,尤其是在当前的“阿片类药物流行”背景下。